This FAQ is organized into ten topic areas. If you're newly exploring these questions, start with Perimenopause & Menopause Basics. If you're researching specific treatments, jump to the section that fits.
Perimenopause is the transitional period before menopause — when ovarian hormone production begins to decline and fluctuate. It typically begins in the mid-to-late 40s and lasts an average of four years, though for some women it can be as short as two years or as long as ten.
Many women refer to perimenopause as "menopause," but technically menopause is the single point in time when a woman has not had a menstrual period for 12 consecutive months. Everything before that is perimenopause; everything after is postmenopause.
The earliest signals are often subtle and easy to miss:
These symptoms result from estrogen and progesterone levels rising and falling unpredictably as the ovaries' output declines.
The average age of menopause in the U.S. is 51. Normal menopause can occur anywhere from age 40 to age 60. Menopause before age 40 is considered premature menopause or premature ovarian insufficiency (POI) and warrants specific medical evaluation.
Several factors can influence timing: smoking (typically earlier menopause), never having children (slightly earlier), genetics, and certain medical conditions or treatments such as chemotherapy or oophorectomy (surgical removal of the ovaries).
It varies dramatically by woman and by symptom. Approximately 75% of women experience hot flashes, and roughly 80% of that group have them for two years or less. However, some women experience hot flashes for a decade or longer.
Sleep disruption, mood changes, and vaginal/urinary symptoms can persist indefinitely without intervention — these don't typically resolve on their own the way some vasomotor symptoms eventually do. Untreated estrogen deficiency also produces long-term consequences like bone loss, cardiovascular risk increases, and cognitive changes.
Multiple mechanisms work together:
The frustrating result: women often gain weight even when eating less and exercising more. Hormone optimization addresses the underlying drivers; lifestyle changes alone often aren't enough once these systems shift.
Estrogen has a powerful protective effect on both cardiovascular and skeletal systems. When estrogen declines:
Heart disease becomes the leading cause of death in postmenopausal women — a fact most women don't fully grasp. Estrogen optimization is one of the most powerful long-term cardiovascular and skeletal interventions available, when started at the appropriate time.
Surgical menopause occurs when both ovaries are removed (bilateral oophorectomy), often during a hysterectomy or as cancer-risk reduction. Medically-induced menopause results from chemotherapy, radiation, or certain medications that suppress ovarian function.
The difference from natural menopause is sudden onset — hormone levels drop dramatically overnight rather than declining gradually over years. Symptoms tend to be more intense, and the long-term health implications (cardiovascular, bone, cognitive) appear sooner. Women who experience surgical or medically-induced menopause often benefit substantially from hormone replacement, particularly when it occurs at a younger age.
Yes. Hormone levels fluctuate during perimenopause, which means ovulation can still occur — sometimes unexpectedly. Pregnancy in perimenopause is possible until you've gone 12 consecutive months without a period (the definition of menopause).
For women who do not want additional pregnancies, contraception should continue throughout perimenopause. This is also relevant when considering hormone therapy, since some HRT protocols include cycle management.
GSM is a relatively recent term that consolidates several symptoms caused by the loss of estrogen in the genital and urinary tissues. It includes:
GSM affects the majority of postmenopausal women and, unlike hot flashes, does not resolve on its own. It tends to progress without treatment. The good news is that it responds very well to several modern interventions — both hormonal and non-hormonal.
HRT (Hormone Replacement Therapy) is the broader term for any therapy that supplements declining hormones. Historically, HRT often referred to synthetic conjugated equine estrogens (derived from pregnant mare urine) and synthetic progestins.
BHRT (Bioidentical Hormone Replacement Therapy) uses hormones that are molecularly identical to those your body produces naturally — bioidentical estradiol, estriol, progesterone, and testosterone. These are typically derived from plant sources (yam or soy) and modified in the lab to match human hormones exactly.
The distinction matters because most of the safety concerns historically associated with "hormone therapy" come from studies using synthetic forms — not bioidentical hormones. Modern BHRT generally has a more favorable safety profile and better tolerability.
For most healthy women without specific contraindications, properly prescribed and monitored BHRT has a strong safety profile. The widespread fear of hormone therapy stems largely from the 2002 Women's Health Initiative (WHI) study, which:
Subsequent analyses by the same investigators have largely revised the original conclusions, particularly for women who begin therapy within 10 years of menopause onset ("the timing hypothesis"). For most healthy women, the benefits of BHRT — improved quality of life, reduced cardiovascular risk, preserved bone density, reduced dementia risk — outweigh the risks when started at the appropriate time.
This is one of the most persistent and misunderstood concerns in women's health. Current evidence supports a more nuanced picture:
Women with a personal history of breast cancer typically cannot use estrogen therapy — but non-hormonal alternatives (vaginal rejuvenation with laser or radiofrequency, PRP-based therapies) work very well for many GSM symptoms.
The main delivery methods include:
The right form depends on which hormones are needed, your lifestyle, your skin's response, your history, and your preference.
A comprehensive female hormone panel should include, at minimum:
Most primary care physicians order only TSH and possibly estradiol — which misses most of the picture. Comprehensive testing is the foundation of personalized therapy.
Different effects appear on different timelines:
The first 90 days typically deliver the most dramatic subjective changes. Ongoing monitoring and dose adjustment help optimize the longer-term response.
Estrogen is the primary hormone driving most menopause-related symptoms — hot flashes, vaginal changes, bone and cardiovascular protection, mood, cognition.
Progesterone balances estrogen's effects on the uterine lining (preventing overgrowth) and has its own benefits: improved sleep, mood calming, possible neuroprotective effects.
If you still have a uterus, you must take progesterone along with systemic estrogen — unopposed estrogen causes endometrial overgrowth and increases endometrial cancer risk. If you've had a hysterectomy, you can take estrogen alone. Progesterone is also sometimes used alone for sleep, mood, or specific perimenopausal patterns.
When properly dosed by an experienced physician, testosterone pellets are safe and effective for women — but the dose matters enormously. Women need only a small fraction of the testosterone dose men require, and over-dosing causes side effects (acne, unwanted hair growth, voice changes, irritability).
Pellets release testosterone steadily over 3–4 months, avoiding the daily highs and lows of creams. Many women find pellets are the most effective and convenient form of testosterone therapy. The keys: experienced physician, appropriate dosing, and ongoing monitoring of both hormone levels and symptoms.
It depends on the specifics. A general family history of breast cancer alone is not necessarily a contraindication — many women with positive family histories use BHRT safely with appropriate monitoring. Known BRCA mutations, personal history of breast cancer, or multiple first-degree relatives with early-onset breast cancer warrant a more cautious conversation.
The decision should be made with a physician who understands both your specific genetic risk profile and the modern evidence on different hormone formulations. Non-hormonal options are excellent fallbacks for women who can't or don't want to use systemic estrogen.
That's a personal decision, not a medical mandate. Some women use BHRT for 5–10 years through the most intense symptom window, then taper. Others continue indefinitely for the long-term cardiovascular, bone, and cognitive benefits.
The conversation should weigh your specific risks, benefits, goals, and how you feel. The old "lowest dose for the shortest time" rhetoric has been largely abandoned by hormone optimization specialists in favor of individualized, lifetime-perspective decisions.
Hot flashes (the medical term is "vasomotor symptoms") result from changes in the hypothalamus — the brain's temperature regulation center — as estrogen levels fluctuate and decline. The hypothalamus essentially becomes hypersensitive, triggering rapid vasodilation, sweating, and a sensation of intense heat in response to even minor temperature shifts.
About 75% of perimenopausal and menopausal women experience hot flashes. They typically last 1–5 minutes and can range from mildly uncomfortable to severely disruptive. Night sweats are essentially hot flashes that occur during sleep.
Strategies that help many women without medication:
For severe hot flashes that disrupt sleep and daily life, hormone replacement therapy is the most effective intervention available — typically reducing frequency and intensity by 80–95%.
Multiple mechanisms collide during the menopause transition:
Hormone optimization — particularly bioidentical progesterone taken at bedtime — addresses several of these mechanisms at once. Many women describe restored sleep as the most transformative effect of starting BHRT.
Yes — and often the first time. Estrogen interacts directly with serotonin, dopamine, and GABA — the neurotransmitter systems that regulate mood, anxiety, and emotional reactivity. As estrogen fluctuates and declines, women who never previously experienced anxiety or depression can develop both.
Many women are placed on SSRIs for these symptoms when the root cause is hormonal. SSRIs can help, but they don't address why the symptoms emerged in the first place — and they can themselves further suppress libido and sexual response. Comprehensive hormone evaluation should always precede long-term psychotropic prescribing for symptoms that emerge in the perimenopausal window.
Estrogen receptors are abundant in regions of the brain involved in memory, attention, and processing speed — particularly the hippocampus and prefrontal cortex. When estrogen drops, these regions don't function as well. The result: word-finding problems, short-term memory lapses, difficulty multitasking, slower processing speed, and the general experience of "brain fog."
For most women, these cognitive changes improve with hormone optimization. Importantly, there's increasing evidence that maintaining estrogen during the perimenopause and early postmenopause window may have long-term protective effects against Alzheimer's disease — though the science is still evolving.
Hormonal anxiety tends to have several distinguishing features:
When hormonal anxiety is properly identified and treated at the hormonal level, women often experience profound improvement — sometimes resolving anxiety that didn't respond to years of other approaches.
Absolutely. Women's bodies produce testosterone in the ovaries and adrenal glands throughout their lives. Testosterone is essential for:
Women's testosterone levels begin declining in their 30s, and by menopause may be only a fraction of peak values. Most physicians never test testosterone in women — yet for many midlife women, low testosterone is the missing piece that explains symptoms that didn't fully resolve with estrogen and progesterone alone.
The most common signs include:
Many women with these symptoms are told their estrogen is "fine" and never have testosterone tested.
The main delivery methods for women:
The dose for women is much smaller than for men — typically about 1/10th of a male dose. Proper dosing is critical because over-dosing produces side effects (acne, unwanted hair growth, oily skin, irritability).
At physiologically appropriate doses for women, no. The side effects you're worried about — male-pattern hair growth (hirsutism), voice deepening, clitoral enlargement, acne — occur with supraphysiologic dosing (too much testosterone).
With appropriate dosing by an experienced physician, most women experience only the benefits: restored libido, energy, muscle tone, and mental sharpness. Monitoring blood levels and clinical symptoms allows ongoing dose adjustment to keep results in the therapeutic window.
In the United States, there is currently no testosterone product specifically FDA-approved for women — though testosterone therapy for women is endorsed by major international medical organizations and is well-supported by clinical evidence.
Most physicians prescribing testosterone for women use FDA-approved testosterone products off-label (in lower doses than approved for men) or use compounded bioidentical testosterone from licensed compounding pharmacies. Both approaches are legal and widely used; the lack of female-specific FDA approval reflects the regulatory pathway, not the strength of the underlying evidence.
Vaginal tissues are estrogen-dependent — they rely on estrogen for thickness, elasticity, blood flow, lubrication, and the maintenance of healthy bacterial flora. When estrogen declines, the vaginal walls thin (atrophy), lose moisture, become more fragile, and may become more alkaline (raising infection risk).
The result: dryness, itching, burning, painful intercourse, recurrent UTIs, and changes in sexual response. Unlike hot flashes, vaginal symptoms do not resolve on their own and typically worsen over time without treatment.
The right treatment depends on severity and personal circumstances:
Combination approaches (e.g., vaginal estrogen plus periodic laser treatments) often deliver the best results.
Vaginal rejuvenation refers to non-surgical procedures that restore vaginal tissue health, moisture, tightness, and sensation. The two main technologies:
Both work through the body's own healing response — stimulating new tissue rather than adding anything foreign. Most protocols involve 3 treatments spaced 4–6 weeks apart, with maintenance treatments every 12–18 months.
Yes — and it's one of the most important applications. Breast cancer survivors taking aromatase inhibitors or tamoxifen often experience severe GSM (vaginal atrophy, dryness, painful intercourse, recurrent UTIs) but typically cannot use estrogen therapy due to recurrence risk.
Vaginal laser and radiofrequency treatments stimulate the tissue's own regenerative response without introducing hormones. For many breast cancer survivors, these treatments have been life-changing — restoring comfort, intimacy, and quality of life that was thought permanently lost.
Always coordinate with your oncologist before starting any treatment.
Most women experience significant improvement after the initial 3-treatment protocol, with results lasting 12–18 months on average. A single maintenance treatment annually or every 18 months sustains the benefits long-term.
Results depend on baseline tissue health, severity of atrophy, whether you're also using hormone therapy, and individual healing response. Women who combine laser/RF with vaginal estrogen or systemic BHRT typically see the most durable, comprehensive results.
Most women report minimal to no discomfort. The procedure typically takes 15–30 minutes and feels like mild warmth or vibration. Topical anesthetic is sometimes used for sensitive patients. No anesthesia, no downtime, and you can drive yourself home and return to normal activities the same day (with brief abstinence from intercourse for a few days post-treatment).
The O-Shot® (Orgasm Shot) is a regenerative procedure that uses your own platelet-rich plasma (PRP). Blood is drawn from your arm, then spun in a high-speed centrifuge to concentrate the platelets and growth factors. The concentrated PRP is then injected into specific areas of the clitoris and the anterior vaginal wall.
The growth factors stimulate the formation of new blood vessels, nerves, and tissue regeneration over the following weeks — improving sensitivity, sexual response, vaginal moisture, and in many cases stress urinary incontinence.
The O-Shot® addresses multiple concerns:
Like the male P-Shot®, the O-Shot® works at the cellular level — regenerating tissue rather than masking symptoms.
For most women, yes. Clinical experience shows:
Results vary based on baseline tissue health, hormonal status, and whether the O-Shot® is used alone or combined with hormone optimization or laser therapy.
The procedure is typically well-tolerated. Topical numbing cream and local anesthetic injection are used before the PRP injection, so most women describe the experience as more uncomfortable than painful. The procedure takes 30–45 minutes total. Most women return to normal activities the same day, with brief abstinence from intercourse for 24–48 hours.
Good candidates include women with:
Not ideal candidates: women with active infections, certain blood disorders, or active gynecologic cancer requiring evaluation.
The O-Shot® typically ranges from $1,500–$2,500 per treatment in physician-led practices, depending on geography, provider experience, and what's included. Some practices offer bundled packages combining the O-Shot® with vaginal laser therapy or hormone optimization for better overall value.
The procedure is generally not covered by insurance because it's classified as elective regenerative medicine. Many practices offer financing.
Yes — and this is one of its most valuable applications. When PRP is injected into the area where stress urinary incontinence surgery would place a sling, it can strengthen the supporting tissue and improve urethral closure. Many women see substantial improvement in stress urinary incontinence symptoms — sometimes avoiding the need for surgical intervention entirely.
For women whose incontinence is significantly affecting quality of life but who aren't ready for surgery, the O-Shot® often provides an excellent middle-ground option.
Stress urinary incontinence (SUI) is leakage that occurs with abdominal pressure — coughing, sneezing, laughing, jumping, lifting, exercising. It's caused by weakened pelvic floor support and/or urethral closure mechanisms. SUI affects an estimated 15 million American women and is the most common type.
Urge incontinence is the sudden, intense urge to urinate followed by involuntary leakage — the "gotta go right now and I might not make it" experience. It's caused by overactive bladder muscle contractions and is sometimes called "neurogenic bladder."
Many women have both ("mixed incontinence"). Treatment differs significantly depending on which type predominates.
The urethra is essentially part of the vaginal wall — and like the vagina, it depends on estrogen for tissue health and moisture. When estrogen declines, the urethra and surrounding tissue become drier, thinner, and less able to maintain a tight seal.
Dr. Ibrahim uses the analogy of a playing card on a table: a dry card slides easily, but a slightly damp card sticks to the surface. The urethra works the same way — vaginal and urethral moisture creates the slight "stickiness" that helps keep urine in the bladder. As things dry out in menopause, that natural mechanism fails.
Add to this the effect of decades of childbirth, gravity, and pelvic floor changes, and incontinence becomes very common in postmenopausal women.
A range of options, from conservative to surgical:
Conservative and regenerative options have advanced considerably and often produce excellent results without surgery. Surgery should typically be the last resort, not the first conversation.
For many women, yes. Modern non-surgical approaches — particularly when combined — have transformed outcomes:
Surgery remains an excellent option for severe cases or when conservative approaches fail — but the proportion of women who actually need surgery has shrunk dramatically with modern regenerative options.
Yes, when done properly. Most women perform Kegels incorrectly — either contracting the wrong muscles, holding too briefly, or not progressing the difficulty appropriately. Working with a pelvic floor physical therapist is far more effective than trying to figure it out alone.
Modern pelvic floor PT often includes biofeedback, electrical stimulation, and progressive strengthening programs. Many women see substantial improvement in 8–12 weeks of proper treatment.
Multiple hormonal and physical changes converge:
The good news: all of these factors are addressable. Most women who pursue comprehensive treatment — hormones, regenerative therapy, and sometimes peptides — see meaningful restoration of libido and sexual response.
For most women, yes — but it usually takes more than estrogen alone. Estrogen restoration improves vaginal comfort, lubrication, mood, and energy. Testosterone restoration is typically what brings desire back. Progesterone supports sleep and emotional regulation. The full picture matters.
Many women whose libido didn't return on estrogen alone experience profound improvement when testosterone is added. This is one reason comprehensive hormone evaluation matters — testing only estrogen misses the hormone most directly tied to female desire.
PT-141 (Bremelanotide, brand name Vyleesi) is a peptide that acts on the melanocortin receptors in the brain to stimulate sexual desire. Unlike Viagra-class drugs that affect blood flow, PT-141 works centrally — it addresses the desire side of the equation rather than the mechanical side.
It's used on-demand, typically 45 minutes to several hours before anticipated intimacy, and is one of the few FDA-approved treatments specifically for low libido in premenopausal women (HSDD — Hypoactive Sexual Desire Disorder). It can also benefit postmenopausal women, though that use is off-label.
Several peptide categories are commonly used:
Peptides work best as part of a comprehensive plan that also addresses hormones, nutrition, sleep, and exercise.
Two FDA-approved medications specifically address low desire in women:
Neither is "Viagra for women" because female sexual function doesn't follow the same primarily-vascular model as male erectile function. The female sexual response is more multidimensional — involving desire, arousal, blood flow, sensation, and emotional context. Addressing it usually requires a multi-pronged approach: hormone optimization, possibly peptides, vaginal health treatments, and sometimes counseling support.
Pricing varies considerably by practice and protocol, but typical ranges:
Comprehensive evaluation and individualized monitoring produce far better outcomes than the cheapest possible protocol. The value question isn't "what's the lowest price" — it's "what's the best return on my investment in feeling like myself again."
Sometimes, partially. Most insurance plans cover certain forms of HRT — particularly oral estrogen, transdermal patches, and oral progesterone. However, insurance often:
Many women find that insurance-constrained HRT produces inferior outcomes compared to physician-led, patient-pay optimization with full lab work and personalized dosing.
Typical pricing in physician-led practices:
Most practices offer financing through CareCredit or similar healthcare lenders.
For the right candidate, the cost-benefit calculation is usually clear. The downstream costs of not treating menopausal hormone decline — depression, weight gain, cardiovascular disease, osteoporosis, declining productivity, relationship strain, loss of intimacy, accelerated aging — far exceed the cost of optimization.
Most women describe physician-led BHRT as the highest-ROI investment they've made in themselves. That said, the value depends entirely on working with the right physician using the right protocol. A poorly run optimization program is worse than no program at all.
Often, yes — for the medical components (labs, physician visits, prescription hormones). HSA and FSA rules vary by plan, but most allow medically necessary hormone replacement, related labs, and physician consultations.
Elective regenerative procedures (O-Shot®, laser/RF vaginal rejuvenation) are typically not HSA/FSA eligible. Always confirm with your plan administrator.
Look for these signals of quality:
Avoid franchise clinics that prescribe identical protocols to every patient regardless of labs or symptoms.
Strong questions to bring to a consultation:
Menopause clinics typically focus on managing menopausal symptoms with conventional HRT. Some are excellent; some are limited to oral or transdermal estrogen plus an SSRI for mood and a sleep aid.
Comprehensive hormone optimization practices treat the entire hormonal system — estrogen, progesterone, testosterone, thyroid, cortisol, growth hormone, and metabolic markers — and often integrate regenerative medicine (O-Shot®, vaginal rejuvenation), peptides, and lifestyle. They're typically patient-pay and produce more durable, holistic results.
The right choice depends on your goals and the complexity of your symptoms.
Biltmore Restorative Medicine & Aesthetics, founded by Dr. George K. Ibrahim — a Duke-trained urologist, Advisory Board member of The Menopause Association, and A4M fellow in anti-aging medicine — is one of the most credentialed women's hormone and menopause practices in Western North Carolina.
The practice offers comprehensive women's hormonal health services including bioidentical hormone replacement (pellets, creams, patches, oral), the O-Shot®, vaginal laser and radiofrequency rejuvenation, peptide therapy, treatment for stress urinary incontinence, and aesthetic services. The Asheville office is located at 1 Vanderbilt Park Dr #230, Asheville, NC 28803. Phone: (828) 505-2885.
Biltmore Restorative Medicine & Aesthetics has a Greenville location at 2249 Augusta St, Greenville, SC 29605, offering the same physician-led care available at the Asheville office. The Greenville practice serves Upstate South Carolina including Spartanburg, Anderson, and the broader I-85 corridor.
Phone: (864) 695-1469.
Many Charlotte and Atlanta women find that the quality of care available at Biltmore Restorative Medicine — about 2 hours from Charlotte, 3.5 hours from Atlanta — exceeds what they can find locally for comprehensive hormone optimization and regenerative women's health care. Combining a treatment visit with a weekend in Asheville or Greenville is common.
Virtual consultations are also available to start the conversation, review labs, and plan treatment before traveling.
Yes. Biltmore Restorative Medicine offers virtual consultations for women exploring treatment from out of area — including consultation, lab review, and treatment planning. In-person visits are still required for procedures (O-Shot®, vaginal rejuvenation, pellet insertion), but a great deal can be accomplished remotely first.
Many out-of-state patients combine a treatment visit with a stay in the Asheville or Greenville area.
Biltmore Restorative Medicine in Asheville, NC is approximately 2 hours west of Charlotte via I-40 and offers physician-led women's hormone optimization, menopause management, and regenerative medicine that many Charlotte residents specifically travel for. The Greenville, SC location is approximately 1.5 hours southwest of Charlotte.
The best clinic depends on your specific needs, but Biltmore Restorative Medicine consistently ranks among the most credentialed and comprehensive options in North and South Carolina because of:
The FAQ covers what we hear most often — but every woman's situation is unique. A consultation with Dr. Ibrahim's team gives you specific answers based on your labs, your symptoms, your history, and your goals.